Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.63 |
| ▸ | JAK2 | O60674 | 2/20 | 0.63 |
| ▸ | RET | P07949 | 2/20 | 0.63 |
| ▸ | KDR | P35968 | 2/20 | 0.63 |
| ▸ | GSK3A | P49840 | 2/20 | 0.63 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.63 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.63 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.63 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.63 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.63 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.63 |
| ▸ | PRKACA | P17612 | 2/20 | 0.63 |
| ▸ | CDK8 | P49336 | 2/20 | 0.63 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.63 |
| ▸ | AURKA | O14965 | 1/20 | 0.63 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.63 |
| ▸ | ABL1 | P00519 | 1/20 | 0.63 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.63 |
| ▸ | CSF1R | P07333 | 1/20 | 0.63 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL360789 | 0.82 | DYRK1A (0.77) | CLK4JAK2RETKDRGSK3A | |
| SCHEMBL31265360 | 0.82 | MAP4K4 (0.63) | CLK4JAK2RETKDRGSK3A | |
| SCHEMBL30375110 | 0.82 | GRM5 (0.47) | CLK4JAK2RETKDRGSK3A | |
| SCHEMBL23535573 | 0.82 | MAP4K4 (0.63) | CLK4JAK2RETKDRGSK3A | |
| SCHEMBL10850137 | 0.81 | KDR (0.59) | CLK4JAK2RETKDRGSK3A | |
| SCHEMBL24156283 | 0.81 | KDR (0.54) | CLK4JAK2RETKDRGSK3A | |
| SCHEMBL16562548 | 0.77 | AURKA (1.00) | CLK4JAK2RETKDRGSK3A | |
| SCHEMBL23535563 | 0.77 | DYRK1A (0.58) | CLK4JAK2RETKDRGSK3A | |
| SCHEMBL11626357 | 0.76 | SMN1; SMN2 (0.57) | FYN | |
| SCHEMBL10850315 | 0.75 | DYRK1A (0.66) | CLK4JAK2RETKDRGSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120025336-A | LIN28 inhibitors and methods of use thereof | 加利福尼亚大学董事会 | 2025-05-23 | — | — | CN | disclosed |
| CN-115087657-B | LIN28 inhibitors and methods of use thereof | 加利福尼亚大学董事会 | 2025-01-21 | — | — | CN | disclosed |
| US-20230059009-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-02-23 | — | — | US | disclosed |
| US-20230059009-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-02-23 | — | — | US | disclosed |
| EP-4077332-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | The Regents of the University of California (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-115087657-A | LIN28 inhibitor and method of use thereof | 加利福尼亚大学董事会 | 2022-09-20 | — | — | CN | disclosed |
| WO-2021126779-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021126779-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230059009-A1 | INHIBITORS OF LIN28 AND METHODS OF USE THEREOF | LIN28A, DDX21, BMI1 | CLK4 4080/4885JAK2 1185/4885RET 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.